Treatment of hidradenitis suppurativa with etanercept injection

Archives of Dermatology

Volumn 146, Issue 5, 2010, Pages 501-504

  Adams, David R ^a   Yankura, Jessica A ^a   Fogelberg, Anneli C ^a   Anderson, Bryan E ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INJECTION SITE REACTION; MALE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SKIN MANIFESTATION; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 77952643810     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.72     Document Type: Article

References (26)

1. Poli F, Jemec GB, Revuz J. Clinical presentation. In: Jemec GB, Revuz J, Leyden J, eds. Hidradenitis Suppurativa. Berlin, Germany: Springer; 2006:11-23.
2. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539-563.
3. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145 (5):580-584.
4. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
5. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158(3):567-572. (Pubitemid 351239170)
6. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726-729. (Pubitemid 43374099)
7. Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009; 60(4):565-573.
8. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139(12):1540-1542. (Pubitemid 37523071)
9. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149(5):1046-1049.
10. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158(2):370-374.
11. Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol. 2009;8(2):181-183.
12. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. (Pubitemid 351678129)
13. Usmani N, Clayton TH, Everett S, Goodfield J. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32(2):204-205. (Pubitemid 46233031)
14. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa. J Am Acad Dermatol. 2007;56(4):624-628.
15. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265. (Pubitemid 38608568)
16. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48(2):319-324.
17. Wolkenstein P. Quality of life in hidradenitis suppurativa. In: Jemec GB, Revuz J, Leyden J, eds. Hidradenitis Suppurativa. Berlin, Germany: Springer; 2006:116-119.
18. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809-813.
19. Revuz JE, Canoui-Poitrine P, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa. J Am Acad Dermatol. 2008;59(4):596-601.
20. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2, pt 1): 191-194.
21. Hidradenitis Suppurativa Foundation Inc. HS Patient Assessment Tools. http://www.hs-foundation.org/pdf/assessment.pdf. Accessed October 28, 2009.
22. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211-213.
23. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443-446.
24. Anderson DK, Perry AW. Axillary hidradenitis. Arch Surg. 1975;110(1):69-72.
25. Edlich RF, Silloway KA, Rodeheaver GT, Cooper PH. Epidemiology, pathology, and treatment of axillary hidradenitis suppurativa. J Emerg Med. 1986;4(5):369-378.
26. Grant A, Gonzalez T, Kerdel FA. Long-term efficacy and safety results (52 weeks) of a double-blind, placebo-controlled, crossover trial of infliximab for patients with moderate to severe hidradenitis suppurativa. Paper presented at: The Second International Hidradenitis Suppurativa Research Symposium;March 5, 2009; San Francisco, CA.